To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jan 23, 2013)
Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act. (Thus authorizes the Secretary to implement such drugs in the ESRD-PPS immediately.)
What just happenedFeb 8, 2013
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJan 23, 2013
- Feb 8, 2013Committee
Referred to the Subcommittee on Health.
- Jan 25, 2013Committee
Referred to the Subcommittee on Health.
- Jan 23, 2013IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jan 23, 2013IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jan 23, 2013IntroReferralIntro-H
Introduced in House
- Jan 23, 2013IntroReferral1000
Introduced in House